Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 15(S)-8-iso-prostaglandin F2α and nitric oxide (NO)

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1019, Issue , 2016, Pages 95-111

  Tsikas, Dimitrios ^a   Rothmann, Sabine ^a   Schneider, Jessica Y ^a   Suchy, Maria Theresia ^a   Trettin, Arne ^a   Modun, Darko ^b   Stuke, Nadine ^a   Maassen, Norbert ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF SPLIT   (Croatia)

Author keywords

15(S) 8 iso prostaglandin F2 ; Biomarker; CH acidity; Derivatization; Lipid peroxidation; Oxidative stress; Sample storage

Indexed keywords

ACETONE; ALDEHYDES; ASSAYS; BODY FLUIDS; CARBONYL COMPOUNDS; IONS; ISOTOPES; LIPIDS; MASS SPECTROMETRY; MEDICAL APPLICATIONS; MOLECULAR WEIGHT; NEGATIVE IONS; NITRIC OXIDE; ORGANIC SOLVENTS; OXIDATION; OXIDATIVE STRESS; PLASMA (HUMAN); SOLUTIONS; SOLVENT EXTRACTION;

DERIVATIZATIONS; ELECTRON-CAPTURE NEGATIVE IONS; LIPID PEROXIDATION; QUANTITATIVE DETERMINATIONS; SAMPLE STORAGE; SELECTED REACTION MONITORING; STABLE ISOTOPE DILUTION; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

BIOMARKERS;

8 ISOPROSTAGLANDIN F2 ALPHA; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; EDETIC ACID; FLUOROBENZENE; MALONALDEHYDE; NITRIC OXIDE; PENTAFLUOROBENZYL BROMIDE; THIOBARBITURIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; DEUTERIUM; PROSTAGLANDIN F2 ALPHA;

ACIDITY; ANALYTIC METHOD; ARTICLE; DERIVATIZATION; ELECTRON CAPTURE DETECTION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION MONITORING; ISOTOPE DILUTION ASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIPID PEROXIDATION; MASS FRAGMENTOGRAPHY; MEASUREMENT ACCURACY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLVENT EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; BLOOD; CHEMISTRY; EVALUATION STUDY; INDICATOR DILUTION CURVE; METABOLISM; PROCEDURES; URINE;

BIOMARKERS; DEUTERIUM; DINOPROST; FLUOROBENZENES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INDICATOR DILUTION TECHNIQUES; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY;

EID: 84949940348     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.10.009     Document Type: Article

References (49)

1. Draper H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990, 186:421-431.
2. Giustarini D., Dalle-Donne I., Tsikas D., Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit. Rev. Clin. Lab. Sci. 2009, 46:241-281.
3. Gutteridge J.M.C., Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem. Sci. 1990, 15:129-135.
4. Sinnhuber R.O., Yu T.C., Yu T.C. Characterization of the red pigment formed in the 2-thiobarbituric acid determination of oxidative rancidity. Food Res. 1958, 23:626-633.
5. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 1976, 15:212-216.
6. Yoden K., Iio T. Determination of thiobarbituric acid-reactive substances in oxidized lipids by high-performance liquid chromatography with a postcolumn reaction system. Anal. Biochem. 1989, 182:116-120.
7. Esterbauer H., Schaur F.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
8. Bird R.P., Hung S.S., Hadley M., Draper H.H. Determination of malonaldehyde in biological materials by high-pressure liquid chromatography. Anal. Biochem. 1983, 128:240-244.
9. Wade C.R., Jackson P.G., Van Rij A.M. Quantitation of malondialdehyde (MDA) in plasma, by ion-pairing reverse phase high performance liquid chromatography. Biochem. Med. 1985, 33:291-296.
10. Yu L.W., Latriano L., Duncan S., Hartwick R.A., Witz G. High-performance liquid chromatography analysis of the thiobarbituric acid adducts of malonaldehyde and trans,trans-muconaldehyde. Anal. Biochem. 1986, 156:326-333.
11. 2+ in rat liver microsomes. Biochem. J. 1982, 208:129-140.
12. Cordis G.A., Das D.K., Riedel W. High-performance liquid chromatographic peak identification of 2,4-dinitrophenylhydrazine derivatives of lipid peroxidation aldehydes by photodiode array detection. J. Chromatogr. A 1998, 798:117-123.
13. Deng Y., Boomsma F., Yu P.H. Deamination of methylamine and aminoacetone increases aldehydes and oxidative stress in rats. Life Sci. 1998, 63:2049-2058.
14. Steghens J.-P., van Kappel A.L., Denis I., Collombel C. Diaminonaphtalene, a new highly specific reagent for HPLC-UV measurement of total and free malondialdehyde in human plasma or serum. Free Radic. Biol. Med. 2001, 31:242-249.
15. Fujioka K., Shibamoto T. Improved malonaldehyde assay using headspace solid-phase microextraction and its application to the measurement of the antioxidant activity of phytochemicals. J. Agric. Food Chem. 2005, 53:4708-4713.
16. Cighetti G., Debiasi S., Paroni R., Allevi P. Free and total malondialdehyde assessment in biological matrices by gas chromatography-mass spectrometry: what is needed for an accurate detection. Anal. Biochem. 1999, 266:222-229.
17. Maboudou P., Mathieu D., Bachelet H., Wiart J.F., Lhermitte M. Detection of oxidative stress. Interest of GC-MS for malondialdehyde and formaldehyde monitoring. Biomed. Chromatogr. 2002, 16:199-202.
18. Beljean-Leymarie M., Bruna E. Subpicogram determination of malondialdehyde by gas-liquid chromatography with nitrogen phosphorus detector. I. Standardization. Anal. Biochem. 1988, 173:174-184.
19. Yeo H.C., Helbock H.J., Chyu D.W., Ames B.N. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal. Biochem. 1994, 220:391-396.
20. Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal. Chem. 2000, 72:4064-4072.
21. 2α may be markedly compromised by hemolysis: evidence by GC-MS/MS and potential analytical and biological ramifications. Clin. Biochem. 2010, 43:159-167.
22. Tsikas D., Schneider J.Y., Frölich J.C. Antihypertensive inorganic nitrate and nitrite: what is the underlying mechanism?. Hypertension 2013, 62:e6.
23. 2α. FEBS Lett. 2012, 586:3723-3730.
24. Filipe P., Haigle J., Freitas J., Fernandes A., Mazière J.C., Mazière C., Santus R., Morlière P. Anti- and pro-oxidant effects of urate in copper-induced low-density lipoprotein oxidation. Eur. J. Biochem. 2002, 269:5474-5483.
25. Tsikas D. A proposal for comparing methods of quantitative analysis of endogenous compounds in biological systems by using the relative lower limit of quantification (rLLOQ). J. Chromatogr. B 2009, 877:2241-2251.
26. Tsikas D., Schwedhelm E., Suchy M.T., Niemann J., Gutzki F.M., Erpenbeck V.J., Hohlfeld J.M., Surdacki A., Frölich J.C. Divergence in urinary 8-iso-PGF(2alpha) (IPF(2alpha)-III 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J. Chromatogr. B 2003, 794:237-255.
27. Tsikas D., Wolf A., Mitschke A., Gutzki F.M., Will W., Bader M. GC-MS determination of creatinine in human biological fluids as pentafluorobenzyl derivative in clinical studies and biomonitoring: inter-laboratory comparison in urine with Jaffe, HPLC and enzymatic assays. J. Chromatogr. B 2010, 878:2582-2592.
28. Schneider J.Y., Rothmann S., Schröder F., Langen J., Lücke T., Mariotti F., Huneau J.F., Frölich J.C., Tsikas D. Effects of chronic oral l-arginine administration on the l-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: l-arginine prevents renal loss of nitrite, the major NO reservoir. Amino Acids 2015, 47:1961-1974.
29. Lachmuth J.Y. The APAV Pilot Study. l-Arginine in Patients with Peripheral Arterial Occlusive Disease. PhD Thesis 2007, Hannover Medical School, Hannover. http://d-nb.info/991618793/34.
30. Rothmann S. Pilot Study on the Effects of l-Arginine in Patients with Coronary Artery Disease after Angioplasty and Method Development for the Determination of DMA in Plasma as PFB Derivative. PhD Thesis 2009, Hannover Medical School, Hannover. http://d-nb.info/1007632712/34.
31. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
32. Stichtenoth D.O., Marhauer V., Tsikas D., Gutzki F.M., Frölich J.C. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int. 2005, 68:2197-2207.
33. Chobanyan K., Mitschke A., Gutzki F.M., Stichtenoth D.O., Tsikas D. Accurate quantification of dimethylamine (DMA) in human plasma and serum by GC-MS and GC-tandem MS as pentafluorobenzamide derivative in the positive-ion chemical ionization mode. J. Chromatogr. B 2007, 851:240-249.
34. Hüttel R. Über malondialdehyd. 1. Mitteilung. Ber. Detsch. Chem. Ges. 1941, 74:1825-1829.
35. Osman M.M. The acidity of malondialdehyde and the stability of its complexes with nickel(II) and copper(II). Helv. Chim. Acta 1972, 55:239-244.
36. Draper H.H., Hadley M., Lissemore L., Liang N.M., Cole P.D. Identification of N-epsilon-(2-propenal) lysine as a major urinary metabolite of malondialdehyde. Lipids 1988, 23:626-628.
37. McGirr L.G., Hadley M., Draper H.H. Identification of N alpha-acetyl-epsilon-(2-propenal) lysine as a urinary metabolite of malondialdehyde. J. Biol. Chem. 1985, 260:15427-15431.
38. Hadley M., Draper H.H. Identification of N-(2-propenal) serine as a urinary metabolite of malondialdehyde. FASEB J. 1988, 2:138-140.
39. Hadley M., Draper H.H. Identification of N-(2-propenal) ethanolamine as a urinary metabolite of malondialdehyde. Free Radic. Biol. Med. 1989, 6:49-52.
40. Tomita M., Okuyama T., Hatta Y., Kawaj S. Determination of free malonaldehyde by gas chromatography with an electron-capture detector. J. Chromatogr. 1990, 526:174-179.
41. 2 and malondialdehyde formation following administration of aspirin to man. Thrombosis Res. 1979, 15:405-413.
42. Wallner S., Hermetter A., Mayer B., Wascher T.C. The alpha-amino group of l-arginine mediates its antioxidant effect. Eur. J. Clin. Invest. 2001, 31:98-102.
43. Evans J.D., Oleksyshyn N.L., Waldron J.M. Autoxidation of polyunsaturated fatty acids in human plasma. J. Appl. Physiol. 1956, 9:301-303.
44. Schwedhelm E., Benndorf R.A., Böger R.H., Tsikas D. Mass spectrometric analysis of F2-isoprostanes: markers and mediators in human disease. Curr. Pharmac. Anal. 2007, 3:39-51.
45. Siems W.G., Zollner H., Grune T., Esterbauer H. Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-dihydroxynonene is not the main product. J. Lipid Res. 1997, 38:612-622.
46. Suttnar J., Masova L., Dyr J.E. Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. J. Chromatogr. B 2001, 751:193-197.
47. Kanabrocki E.L., Murray D., Hermida R.C., Scott G.S., Bremner W.F., Ryan M.D., Ayala D.E., Third J.L., Shirazi P., Nemchausky B.A., Hooper D.C. Circadian variation in oxidative stress markers in healthy and type II diabetic men. Chronobiol. Int. 2002, 19:423-439.
48. Helmersson J., Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukotrienes Essent. Fatty Acids 1999, 61:203-205.
49. Modun D., Krnic M., Vukovic J., Kokic V., Kukoc-Modun L., Tsikas D., Dujic Z. Plasma nitrite concentration decreases after hyperoxia-induced oxidative stress in healthy humans. Clin. Physiol. Funct. Imaging 2012, 32:404-408.